These results, which reinforce those from previously published preclinical studies in smaller animals, might represent an important step towards future clinical translation of this treatment strategy, although further investigations are needed to confirm the safety of modulating RAGE in patients with ARDS. The gene discussed is AGER; the disease is acute respiratory distress syndrome.